{"contentid": 488680, "importid": NaN, "name": "HiberCell closes $67.4 million Series B financing", "introduction": "Launched in February 2019 with $60 million financing, US biotech HiberCell today announced that it has completed a Series B financing round for gross proceeds of $67.4 million.", "content": "<p>Launched in February 2019 with $60 million financing, US biotech HiberCell today announced that it has completed a Series B financing round for gross proceeds of $67.4 million. Concurrent to this financing, HiberCell closed on a $30 million debt facility with Hercules Capital (NYSE: HTGC).</p>\n<p>The funds will be used to advance HiberCell&rsquo;s pipeline of clinical product candidates focused on preventing cancer relapse and metastasis.</p>\n<p>New investors include: Huizenga Capital Management, Monashee Investment Management, with funds managed by Tekla Capital Management, Hercules Capital, Mount Sinai Innovation Partners and other undisclosed investors</p>\n<p>&ldquo;We are excited to have the support of these sophisticated investors, who understand that delaying or preventing cancer relapse and metastasis requires that we rethink cancer and understand the mechanistic drivers of cancer progression,&rdquo; said Alan Rigby, co-founder and chief executive of HiberCell, adding: &ldquo;We are enthusiastic about our progress and look forward to advancing our clinical pipeline: driving Imprime PGG into two new Phase II trials, while generating first in human safety, tolerability and pharmacokinetic data in a Phase Ia trial with our PERK inhibitor HC-5404.&rdquo;</p>\n<p>&ldquo;HiberCell has taken a pioneering approach to an evolving cancer paradigm through demonstratable expertise in defining and harnessing adaptive stress biology as well as innate immune activation with a focus on tackling cancer relapse, metastatic disease, and tumor dormancy,&rdquo; said Dr Rene Mora, portfolio manager of Monashee Investment Management.</p>\n<p>&nbsp;</p>", "date": "2021-05-20 10:53:00", "meta_title": "HiberCell closes $67.4 million Series B financing", "meta_keywords": "HiberCell, Series B, Financing, Pipeline, HC-5404", "meta_description": "HiberCell closes $67.4 million Series B financing", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-20 10:52:06", "updated": "2021-05-20 11:01:19", "access": NaN, "url": "https://www.thepharmaletter.com/article/hibercell-closes-67-4-million-series-b-financing", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "medicines_money_stock_large.jpg", "image2id": "medicines_money_stock_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Oncology", "topic_tag": "Business Financing, One to Watch Companies, Research", "geography_tag": "USA", "company_tag": "HiberCell", "drug_tag": "HC-5404", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-20 10:53:00"}